How we approach suppressive antibiotic therapy (SAT) following debridement, antibiotics, and implant retention for prosthetic joint infection.
Nicolás W Cortés-PenfieldMartin KrsakLaura DamioliMichael HenryJessica SeidelmanAngela HewlettLaura CertainPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
The optimal treatment of prosthetic joint infection (PJI) remains uncertain. Patients undergoing debridement and implant retention (DAIR) receive extended antimicrobial treatment, and some experts leave patients at perceived highest risk of relapse on suppressive antibiotic therapy (SAT). In this narrative review, we synthesize the literature concerning the role of SAT to prevent treatment failure following DAIR, attempting to answer three key questions: 1) What factors identify patients at highest risk for treatment failure after DAIR (i.e. patients with the greatest potential to benefit from SAT)? 2) Does SAT reduce the rate of treatment failure after DAIR? And 3) What are the rates of treatment failure and adverse events necessitating treatment discontinuation in patients receiving SAT? We conclude by proposing risk-benefit stratification criteria to guide use of SAT after DAIR for PJI, informed by the limited available literature.